Dry Age-Related Macular Degeneration Market Size Business Outlook and Opportunities for Investors to 2033
Dry Age-Related Macular Degeneration Market Overview
Dry age-related macular degeneration (AMD) is a progressive eye disorder characterized by the thinning of the macula, the central part of the retina, leading to gradual vision loss in older adults. Unlike the wet form of AMD, the dry type develops more slowly but remains the most prevalent form, accounting for nearly 80–90% of AMD cases globally. With aging populations and increasing life expectancy, the burden of dry AMD on healthcare systems is growing significantly. Effective diagnostics, treatment pipelines, and preventive therapies are essential to manage patient outcomes and reduce long-term economic and social costs associated with vision impairment.
Market Size & Growth Rate
According to Straits Research, the global dry age-related macular degeneration market size was valued at USD 1.89 billion in 2024 and is projected to grow from USD 2.02 billion in 2025 to USD 3.51 billion by 2033, expanding at a CAGR of 7.13% during 2025–2033.
Key Drivers of Growth
The market is driven by the rapid increase in the elderly population worldwide, with age being the most critical risk factor for AMD. Advances in genetic research and a deeper understanding of retinal biology are accelerating the development of novel therapeutics targeting disease progression. Rising awareness of early detection, coupled with growing investments in ophthalmology R&D, are fueling innovation in diagnostic and treatment solutions. In addition, strategic collaborations among pharmaceutical companies, biotech firms, and academic research institutions are supporting the expansion of clinical trials and treatment pipelines. Technological advancements in imaging modalities, such as optical coherence tomography (OCT), are also enhancing diagnosis and monitoring, further stimulating market growth.
📌 Request Sample @ https://straitsresearch.com/report/dry-age-related-macular-degeneration-market
Key Competitors in the Dry Age-Related Macular Degeneration Market
Apellis Pharmaceuticals, Inc.
Astellas Pharma Inc. (Iveric Bio)
Hoffmann-La Roche AG (Genentech, Inc.)
Disc Medicine, Inc. (Gemini Therapeutics, Inc.)
Ionis Pharmaceuticals
NGM Biopharmaceuticals
Annexon Biosciences
AstraZeneca (Alexion Pharmaceuticals)
Boehringer Ingelheim
ONL Therapeutics
Biogen
Novartis AG
Stealth Biotherapeutics Corp.
Market Segmentation
By Stage
Early Age-Related Macular Degeneration
Intermediate Age-Related Macular Degeneration
Late Age-Related Macular Degeneration
By Age Group
Above 75 Years
Above 60 Years
Above 40 Years
By Route of Administration
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
📌 Get Detailed Segmentation @ https://straitsresearch.com/report/dry-age-related-macular-degeneration-market/segmentation
Key Trends & Innovations
The market is witnessing innovation in complement pathway inhibitors, gene therapies, and regenerative medicine approaches to slow or halt disease progression. Digital health tools and AI-based retinal imaging are improving screening accuracy and enabling earlier intervention. Additionally, the growing adoption of teleophthalmology and online pharmacies is expanding access to care, particularly for aging populations in remote areas.
Regional Insights & Market Share
North America leads the market, supported by advanced healthcare infrastructure, higher diagnosis rates, and robust R&D investments from leading pharmaceutical companies.
Europe follows closely, with significant government-backed initiatives in elderly care and ophthalmic disease management.
Asia-Pacific is projected to record the fastest growth due to rising geriatric populations in countries such as Japan, China, and India, along with increasing adoption of advanced diagnostic technologies.
Latin America and Middle East & Africa are emerging markets, where growing awareness and expanding access to ophthalmology services are expected to drive moderate but steady growth.
Challenges/Restraints
Key challenges include the absence of curative treatments for dry AMD, high R&D costs, and lengthy regulatory approval processes for new therapies. Limited awareness in developing regions and affordability barriers further constrain market expansion.
Future Outlook & Strategic Implications
The dry AMD market is expected to advance steadily, with opportunities centered on targeted therapies, regenerative medicine, and personalized treatment strategies. Pharmaceutical players are likely to prioritize clinical pipeline expansion, strategic partnerships, and AI-enabled diagnostic innovations to address unmet patient needs. Increasing integration of online distribution channels and teleophthalmology services will also shape the industry’s future landscape.
About StraitsResearch
StraitsResearch delivers industry-leading analysis and intelligence across multiple sectors, empowering businesses, investors, and strategists with the data they need to make informed decisions. Our team of analysts combines rigorous research methodologies with deep market understanding to provide actionable insights and forecasts.
Contact:🌐 Website: https://straitsresearch.com/📧 Email: sales@straitsresearch.com🏢 Address: Siddhi Tower, Office C & D, 4th Floor, Pune